Recombinant human erythropoietin-CTP fusion protein production process and application

A technology of fusion protein and -CTP, which is applied in the direction of drug combination, peptide/protein composition, recombinant DNA technology, etc., can solve the problems of frequent administration of patients and short half-life of EPO in vivo
CN102994547AActive Publication Date: 2013-03-27哈药集团股份有限公司 +1
7 Cites 8 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
哈药集团股份有限公司
Publication Date
2013-03-27

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a recombinant human erythropoietin-CTP fusion protein production process. The process is characterized in that a microcarrier suspension perfusion culture technology or a serum-free suspension fed-batch culture technology is adopted as a recombinant engineering cell line culture manner. The invention also discloses a recombinant human erythropoietin-CTP fusion protein purifying process. Through optimization, a simple process flow is obtained, such that high-purity and high-activity recombinant human erythropoietin-CTP fusion protein is obtained. The invention also relates to the ticokinetics study of the recombinant human erythropoietin-CTP fusion protein in monkey bodies, and the application of the recombinant human erythropoietin-CTP fusion protein in treating rat renal anemia.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of biopharmaceutical technology. It specifically relates to a production process of a fusion protein of recombinant human erythropoietin and human chorionic gonadotropin beta subunit carboxyl terminal peptide, including the acquisition of recombinant engineered cell lines of the fusion protein, cell culture and protein purification The technical method and the application of the recombinant human erythropoietin-CTP fusion protein in the pharmacokinetic experiment of monkeys and the treatment of renal anemia in rats. Background technique

[0002] EPO is a glycoprotein mainly produced by the kidney with a molecular weight of about 35KD. It is the main hormone regulating erythroid hematopoiesis in the human body and plays an important regulatory role in the proliferation, differentiation and maturation of erythroid progenitor cells. At present, the demand for EPO in my country is increasing year by year, but ordinary EP...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More